Tuesday, September 15, 2026
26.9 C
Bengaluru

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian...

Private equity does not pay a billion-dollar multiple simply because a company describes itself...

Medical Reps—Lessons From The West: The Old Model is Dead

The Core Conclusion The Western pharma industry is not simply...

Pharmacy of the World Pricing Paradox

India occupies an extraordinary position in global pharmaceuticals. It...

How To See Dr Reddy’s Nestle In The Wellness Shift

GLP-1 medicines such as semaglutide and tirzepatide are changing...

How To Power The India Biopharma Regulatory Revolution Now

Beyond the Pharmacy of the World: Why India's Biopharma...

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...

Mounjaro is the Exceptional Growth Story: Ranks #1

The July Brand Monitor by Pharmarack shows a healthy...

Sun Pharma: In the Eye of the Storm of Ophthalmologists

The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...

Platforms Are Owning the Patient While Pharma Waits

The future of experimental medicine is not simply a...

Topics

Don't Miss MedicinMan Updates

Hot this week

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

Blinkit, Zepto, Instamart: Who Will Own India’s At‑Home Diagnostics Market?

India’s diagnostics market is undergoing a quiet but profound...
spot_img

Follow Us

Popular Categories

Video Insights

spot_imgspot_img

Headlines

Pharmacy of the World Pricing Paradox

India occupies an extraordinary position in global pharmaceuticals. It supplies around 20 per cent of the world’s generic medicines...

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

India has two very different pharmaceutical regulators living inside the same government. Through the National Pharmaceutical Pricing Authority, or...

Exclusive Articles

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market. Mounjaro, Eli Lilly’s tirzepatide, is now India's No. 1 pharmaceutical...

Music

MedicinMan Pharma Pulse: August 2026

🚀 The Mega-Merger That Wasn't Early August saw the...

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...

How To See Dr Reddy’s Nestle In The Wellness Shift

GLP-1 medicines such as semaglutide and tirzepatide are changing...

How To Power The India Biopharma Regulatory Revolution Now

Beyond the Pharmacy of the World: Why India's Biopharma...

Food

How To See Dr Reddy’s Nestle In The Wellness Shift

GLP-1 medicines such as semaglutide and tirzepatide are changing...

How To Power The India Biopharma Regulatory Revolution Now

Beyond the Pharmacy of the World: Why India's Biopharma...

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market....

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...

Samuel Paradise

Manuela Cole

Keisha Adams

George Pharell

spot_imgspot_img

Leaders Speak

Business leaders sharing their insights

K. Hariram
8 POSTS
Raja Reddy
5 POSTS